Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.30 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.30 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436025 | 1.00 | KIF11 (0.34) | KIF11MEN1LMNAKMT2ADUT | |
| SCHEMBL19349124 | 0.88 | DUT (0.39) | KIF11MEN1KMT2ADUTTSHR | |
| SCHEMBL19349125 | 0.88 | DUT (0.39) | KIF11MEN1KMT2ADUTTSHR | |
| SCHEMBL8893033 | 0.83 | CYP1A2 (0.37) | KMT2AFOLH1TSHR | |
| SCHEMBL8892535 | 0.83 | CYP1A2 (0.37) | KMT2AFOLH1TSHR | |
| SCHEMBL25182246 | 0.80 | PRSS1 (0.37) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4738904 | 0.80 | EPOR (0.42) | MDM2TSHR | |
| SCHEMBL5548812 | 0.80 | EPOR (0.42) | MDM2TSHR | |
| SCHEMBL25178739 | 0.79 | FFAR1 (0.36) | MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL25179548 | 0.79 | CYP1A2 (0.34) | KMT2AFOLH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355931-B1 | PROTEIN CONJUGATES | NOVO NORDISK AS (DK) | 2024-06-26 | — | — | EP | disclosed |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| EP-4017866-A1 | METHODS OF MAKING INCRETIN ANALOGS | Eli Lilly and Company (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11292825-B2 | Protein conjugates | NOVO NORDISK A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| WO-2021034815-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20200306382-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2020-10-01 | — | — | US | disclosed |
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2020-04-02 | — | — | US | disclosed |
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20180282387-A1 | Protein Conjugates | NOVO NORDISK AS (DK) | 2018-10-04 | — | — | US | disclosed |
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2018-08-09 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20130143815-A1 | GROWTH HORMONE CONJUGATES | NOVO NORDISK HEALTH CARE AG (CH) | 2013-06-06 | — | — | US | disclosed |
| EP-2595661-A1 | GROWTH HORMONE CONJUGATES | Novo Nordisk Health Care AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| EP-2525834-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |
| WO-2012010516-A1 | GROWTH HORMONE CONJUGATES | NOVO NORDISK HEALTH CARE AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-15 | — | — | US | disclosed |
| WO-2011089255-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102568-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KIF11 1792/4885MEN1 335/4885LMNA 2657/4885 |
| US-11292825-B2 | Protein conjugates | DNPEP, KRTCAP2, FCGRT | KIF11 2049/4885MEN1 1738/4885LMNA 4651/4885 |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | KIF11 1712/4885MEN1 790/4885LMNA 4446/4885 |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | KIF11 1856/4885MEN1 335/4885LMNA 3124/4885 |
| US-20180221501-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | KIF11 1712/4885MEN1 790/4885LMNA 4446/4885 |
| US-20180282387-A1 | Protein Conjugates | DNPEP, KRTCAP2, FCGRT | KIF11 2049/4885MEN1 1738/4885LMNA 4651/4885 |
| US-20200306382-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | KIF11 1712/4885MEN1 790/4885LMNA 4446/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KIF11 1792/4885MEN1 335/4885LMNA 2657/4885 |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | KIF11 1847/4885MEN1 376/4885LMNA 2693/4885 |
| US-20130143815-A1 | GROWTH HORMONE CONJUGATES | GHRHR, GHSR, GHITM | KIF11 545/4885MEN1 389/4885LMNA 4760/4885 |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | F13B, F13A1, F2 | KIF11 1676/4885MEN1 2774/4885LMNA 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.